KIT Mutations in AML by Fragment Analysis and Sequencing
2002437
Ordering Recommendation
Prognostication in core-binding factor-related (CBF) AML.
Mnemonic
KIT AML
Methodology
Polymerase Chain Reaction/Fragment Analysis/Sequencing
Performed
DNA isolation: Sun-Sat
Assay:
Sun, Tue, Thu
Reported
12-14 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA) or pink (K2EDTA). OR bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood (Min: 1 mL) OR 3 mL bone marrow (Min: 1 mL).  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemoloyzed specimens.  
Remarks
  
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS  
Note
 
CPT Code(s)
81404
Components
Component Test Code*Component Chart Name
2002439Kit Mutations in AML
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • CBF AML testing
  • CKIT
  • Exon 8 and 17
  • GST8
  • KIT ex 8
  • KIT exon 8